avita medical (http://www.avitamedical.com/) is a publicly listed regenerative medicine company trading on the australian stock exchange (asx:avh) and otc markets (otcqx:avmxy). the company’s lead product, recell® is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. recell is patented, ce-marked for europe, tga- registered in australia, and sfda-cleared in china. recell is not available for sale in the united states; in the us recell is an investigational device limited by federal law to investigational use.
Company profile
Ticker
RCEL, AVHHL
Exchange
Website
CEO
Michael Perry
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Avita Medical, Ltd., Avita Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
AVITA Medical Pty Limited • AVITA Medical Americas, LLC • AVITA Medical Europe Limited • Visiomed Group Pty Ltd • C3 Operations Pty Ltd • Infamed Pty Ltd ...
IRS number
202578762
RCEL stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
23 Apr 24
ARS
2023 FY
Annual report to shareholders
23 Apr 24
8-K
AVITA Medical Updates Expected First Quarter 2024 Revenue
11 Apr 24
PRE 14A
Preliminary proxy
4 Apr 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
22 Feb 24
8-K
AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update
10 Jan 24
8-K
AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year
9 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Departure of Directors or Certain Officers
23 Oct 23
Transcripts
RCEL
Earnings call transcript
2023 Q4
22 Feb 24
RCEL
Earnings call transcript
2023 Q3
9 Nov 23
RCEL
Earnings call transcript
2023 Q2
10 Aug 23
RCEL
Earnings call transcript
2023 Q1
11 May 23
RCEL
Earnings call transcript
2022 Q4
23 Feb 23
RCEL
Earnings call transcript
2022 Q3
11 Nov 22
RCEL
Earnings call transcript
2022 Q2
12 Aug 22
RCEL
Earnings call transcript
2022 Q1
13 May 22
RCEL
Earnings call transcript
2021 Q4
1 Mar 22
RCEL
Earnings call transcript
2022 Q1
9 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Jun 21 | Jun 20 | Jun 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 50.85 mm | 50.85 mm | 50.85 mm | 50.85 mm | 50.85 mm | 50.85 mm |
Cash burn (monthly) | (no burn) | (no burn) | 3.10 mm | 3.02 mm | 2.99 mm | 2.55 mm |
Cash used (since last report) | n/a | n/a | 21.15 mm | 20.62 mm | 20.40 mm | 17.38 mm |
Cash remaining | n/a | n/a | 29.70 mm | 30.23 mm | 30.46 mm | 33.48 mm |
Runway (months of cash) | n/a | n/a | 9.6 | 10.0 | 10.2 | 13.1 |
Institutional ownership, Q2 2023
29.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 79 |
Opened positions | 27 |
Closed positions | 18 |
Increased positions | 25 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 126.57 bn |
Total shares | 7.61 mm |
Total puts | 46.80 k |
Total calls | 52.60 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 1.67 mm | $28.42 bn |
Vanguard | 1.35 mm | $22.96 bn |
Geode Capital Management | 475.16 k | $8.08 bn |
STT State Street | 452.23 k | $7.69 bn |
Pura Vida Investments | 426.32 k | $7.25 bn |
Millennium Management | 274.10 k | $4.66 bn |
NTRS Northern Trust | 217.90 k | $3.71 bn |
Russell Investments | 215.52 k | $3.67 bn |
IVZ Invesco | 177.03 k | $3.01 bn |
EAM Investors | 173.76 k | $2.96 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Feb 24 | O'Toole David D | Common Stock | Buy | Acquire P | No | No | 17.43 | 250 | 4.36 k | 18,734 |
28 Feb 24 | O'Toole David D | Common Stock | Buy | Acquire P | No | No | 17.38 | 1,000 | 17.38 k | 18,484 |
3 Jan 24 | O'Toole David D | Stock Options Common Stock | Grant | Acquire A | No | No | 12.64 | 125,000 | 1.58 mm | 125,000 |
26 Dec 23 | James Corbett | Common Stock | Sell | Dispose S | No | No | 13.29 | 1,445 | 19.20 k | 11,580 |
21 Dec 23 | Cook Jeremy Curnock | Common Stock | Sell | Dispose S | No | No | 12.49 | 2,500 | 31.23 k | 20,614 |
13 Dec 23 | Cook Jeremy Curnock | Common Stock | Sell | Dispose S | No | No | 12.27 | 2,518 | 30.90 k | 20,596 |
News
Nasdaq Jumps 250 Points; Crude Oil Down 1%
11 Apr 24
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
11 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
11 Apr 24
Dow Dips 100 Points; CarMax Earnings Miss Views
11 Apr 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
11 Apr 24
Press releases
AVITA Medical to Announce First Quarter 2024 Financial Results
15 Apr 24
AVITA Medical Updates Expected First Quarter 2024 Revenue
10 Apr 24
AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement
29 Feb 24
AVITA Medical to Host Investor Webinar Briefing
23 Feb 24
AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
22 Feb 24